Y-mAbs Therapeutics
MSK spin-out that commercialises naxitamab, the humanised anti-GD2 antibody for relapsed neuroblastoma, and develops pretargeted radioimmunotherapy.
Naxitamab (Danyelza, accelerated approval November 2020); omburtamab (B7-H3, 131I) rejected by FDA in 2022; SADA pretargeted radioimmunotherapy platform (GD2-SADA, 177Lu) in phase 1.
Pages like this
not linked directly; found by shared links- TrialNaxitamab Study 201
Shares Naxitamab, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares Naxitamab, GD2 (disialoganglioside), Neuroblastoma (paediatric).
- IdeaGD2 CAR-T as consolidation in high-risk neuroblastoma
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TrialCOG ANBL0032
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaOne global paediatric cancer development plan instead of separate FDA and EMA plans
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TrialGD2-CART01 (Bambino Gesù phase 1/2)
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TermINRG staging and risk groups
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaGuaranteed-quality childhood cancer medicines free of charge in 50 countries
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets.